These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9569192)

  • 1. High sensitivity detection of activated factor IX: application to the analysis of different therapeutical factor IX concentrates and prothrombin complexes.
    Kusch M; Seitz R; König H
    Thromb Haemost; 1998 Apr; 79(4):778-83. PubMed ID: 9569192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of seminal factor IX and factor IXa in fertile, nonfertile, and vasectomy subjects: a step closer toward identifying a functional clotting system in human semen.
    Lwaleed BA; Greenfield RS; Hicks J; Birch BR; Cooper AJ
    J Androl; 2005; 26(1):146-52. PubMed ID: 15611579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
    Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
    Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
    Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collaborative study on assays of activated FIX (FIXa). On behalf of the factor VIII and factor IX subcommittee of the ISTH. International Society on Thrombosis and Haemostasis.
    Gray E; Walker D; Heath A; Barrowcliffe TW
    Thromb Haemost; 1996 Dec; 76(6):1114-7. PubMed ID: 8972040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro investigation of prothrombin complex concentrates.
    Römisch J; Bonik K; Müller HG
    Semin Thromb Hemost; 1998; 24(2):175-81. PubMed ID: 9579640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition.
    Kolkman JA; Mertens K
    Biochem J; 2000 Sep; 350 Pt 3(Pt 3):701-7. PubMed ID: 10970782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies.
    Scheiflinger F; Dockal M; Rosing J; Kerschbaumer RJ
    J Thromb Haemost; 2008 Feb; 6(2):315-22. PubMed ID: 18088341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
    Lundblad RL; Kingdon HS; Mann KG; White GC
    Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates.
    Dusel CH; Grundmann C; Eich S; Seitz R; König H
    Blood Coagul Fibrinolysis; 2004 Jul; 15(5):405-11. PubMed ID: 15205589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding.
    Schmidt AE; Stewart JE; Mathur A; Krishnaswamy S; Bajaj SP
    J Mol Biol; 2005 Jul; 350(1):78-91. PubMed ID: 15913649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIIIa regulates substrate delivery to the intrinsic factor X-activating complex.
    Panteleev MA; Ananyeva NM; Greco NJ; Ataullakhanov FI; Saenko EL
    FEBS J; 2006 Jan; 273(2):374-87. PubMed ID: 16403024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa.
    Neuenschwander PF
    Biochemistry; 2004 Mar; 43(10):2978-86. PubMed ID: 15005634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase.
    Jenkins PV; Dill JL; Zhou Q; Fay PJ
    Biochemistry; 2004 May; 43(17):5094-101. PubMed ID: 15109268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
    Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.